<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02148120</url>
  </required_header>
  <id_info>
    <org_study_id>CCD-01535BA1-01</org_study_id>
    <nct_id>NCT02148120</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Acute Bronchodilator Effect of CHF1535 NEXThaler</brief_title>
  <official_title>A Phase II, Multicentre, Double-blind, Randomised, 5-way Crossover Study to Test the Non-inferiority of the Acute Bronchodilator Effect of CHF 1535 200/6 µg NEXThaler Versus CHF 1535 100/6 µg NEXThaler in Partially Controlled and Uncontrolled Adult Asthmatic Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiesi Farmaceutici S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chiesi Farmaceutici S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to demonstrate the non-inferiority in terms of acute bronchodilator
      effect between a single dose of CHF 1535 NEXThaler 200/6 µg and a single dose of CHF 1535
      NEXThaler 100/6 µg at two dose levels in partially controlled and uncontrolled asthmatic
      patients.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>FEV1 Area under the curve</measure>
    <time_frame>until 12 h post dose</time_frame>
    <description>FEV1= Forced expiratory volume in the first second of expiration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>FEV1 peak</measure>
    <time_frame>until 12 h post dose</time_frame>
    <description>Maximum FEV1 value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC area under the curve</measure>
    <time_frame>until 12 h post dose</time_frame>
    <description>FVC = Forced Vital Capacity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FVC peak</measure>
    <time_frame>until 12 h post dose</time_frame>
    <description>Maximum FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>over a period of 5 to 14 weeks</time_frame>
    <description>from the signature of the informed consent until the end of the study, the total duration depends on the duration of the run-in and wash-out periods.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>CHF1535 NEXThaler 100/6, 1 puff</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 NEXThaler 100/6 µg, 4 puffs</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Beclometasone Dipropionate 400 µg + Formoterol Fumarate 24 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 NEXThaler 200/6 µg, 1 puff</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CHF1535 NEXThaler 200/6 µg, 4 puffs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Beclometasone Dipropionate 800 µg + Formoterol Fumarate 24 µg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo NEXThaler</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg</intervention_name>
    <arm_group_label>CHF1535 NEXThaler 100/6, 1 puff</arm_group_label>
    <arm_group_label>CHF1535 NEXThaler 100/6 µg, 4 puffs</arm_group_label>
    <other_name>Foster NEXThaler</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg</intervention_name>
    <arm_group_label>CHF1535 NEXThaler 200/6 µg, 1 puff</arm_group_label>
    <arm_group_label>CHF1535 NEXThaler 200/6 µg, 4 puffs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo NEXThaler</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's written informed consent obtained prior to any study-related procedures.

          -  Male or female aged between 18 and 65 years inclusive;

          -  Evidence for &quot;partially controlled&quot; or &quot;uncontrolled&quot; asthma;

          -  Medium daily dose of previous inhaled corticosteroids (ICS) treatment;

          -  FEV1 between 60% and 85% of the predicted normal values;

          -  A documented positive response to the reversibility test;

          -  Non-smokers or ex-smokers;

          -  A cooperative attitude and ability to be trained in the proper use of a DPI.

        Exclusion Criteria:

          -  Pregnant or lactating women and all women physiologically capable of becoming pregnant
             not willing to use at least one acceptable method of contraception.

          -  Significant seasonal variation in asthma occurring or expected to occur during study
             participation;

          -  History of near fatal asthma, brittle asthma, accident and Emergency treatment or
             hospitalisation for asthma exacerbation in Intensive Care Unit within 1 year before
             screening;

          -  Occurrence of asthma exacerbations or respiratory tract infections in the 4 weeks
             preceding the screening;

          -  Diagnosis of Chronic Obstructive Pulmonary Disease;

          -  History of cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency;

          -  Diagnosis of restrictive lung disease;

          -  Patients treated with oral or parenteral corticosteroids in the previous 8 weeks;

          -  Intolerance or contra-indication to treatment with beta2-agonists and/or inhaled
             corticosteroids;

          -  Allergy, sensitivity or intolerance to study drugs or excipients;

          -  Patients who received any investigational drug within the last 8 weeks before the
             screening;

          -  Patients taking any of the non-permitted concomitant medication;

          -  Subjects unlikely to comply with the study protocol;

          -  Any clinically relevant abnormal value or physical finding at screening;

          -  Significant medical history;

          -  Abnormal and clinically significant 12-lead electrocardiogram;

          -  Patients with low compliance of QVAR intake.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hammersmith Medicines Research</name>
      <address>
        <city>London</city>
        <zip>NW10 7EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Respiratory Clinical Trials, Hearth Lung Centre</name>
      <address>
        <city>London</city>
        <zip>W1G 8HU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicines Evaluation Unit</name>
      <address>
        <city>Manchester</city>
        <zip>M23 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicaltrialsregister.eu/ctr-search/search?query=2013-004826-27</url>
    <description>Study Record on EU Clinical Trials Register including results</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2014</study_first_submitted>
  <study_first_submitted_qc>May 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <last_update_submitted>March 28, 2017</last_update_submitted>
  <last_update_submitted_qc>March 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 29, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Bronchodilator Agents</mesh_term>
    <mesh_term>Beclomethasone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

